Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$2.54
-4.2%
$1.97
$0.96
$3.87
$230.89M2.521.95 million shs373,747 shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$3.98
-4.7%
$3.73
$0.53
$5.78
$648.16M0.293.85 million shs887,731 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.28
-1.5%
$1.68
$0.51
$2.53
$1.01B0.972.80 million shs3.40 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.12
-0.4%
$1.17
$0.98
$1.60
$841.93M1.422.65 million shs690,977 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-7.02%-0.75%+18.30%+112.00%+7.72%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-1.18%-6.08%+14.88%-9.15%+487.99%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+15.50%+41.72%+34.30%+76.34%+229.53%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.75%+1.82%-3.45%-8.20%-10.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$2.54
-4.2%
$1.97
$0.96
$3.87
$230.89M2.521.95 million shs373,747 shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$3.98
-4.7%
$3.73
$0.53
$5.78
$648.16M0.293.85 million shs887,731 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.28
-1.5%
$1.68
$0.51
$2.53
$1.01B0.972.80 million shs3.40 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.12
-0.4%
$1.17
$0.98
$1.60
$841.93M1.422.65 million shs690,977 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
-7.02%-0.75%+18.30%+112.00%+7.72%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-1.18%-6.08%+14.88%-9.15%+487.99%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+15.50%+41.72%+34.30%+76.34%+229.53%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.75%+1.82%-3.45%-8.20%-10.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.00
Hold$5.0096.85% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.43
Hold$6.2356.81% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.33
Hold$4.55100.00% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.5539.01% Upside

Current Analyst Ratings Breakdown

Latest CDXS, OPK, IRWD, and LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/11/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Boost Price TargetBuy$2.30 ➝ $3.10
5/8/2026
Codexis, Inc. stock logo
CDXS
Codexis
UpgradeSell (E+)Sell (D-)
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/27/2026
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Reiterated RatingSell (D+)
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
3/23/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Reiterated RatingBuy$6.00
3/12/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Set Price Target$6.00
3/12/2026
Codexis, Inc. stock logo
CDXS
Codexis
Set Price Target$5.00
3/12/2026
Codexis, Inc. stock logo
CDXS
Codexis
Reiterated RatingOverweight
3/10/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Boost Price TargetBuy$2.10 ➝ $2.30
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$70.39M3.28N/AN/A$0.56 per share4.54
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$296.15M2.19$0.24 per share16.39($1.61) per share-2.47
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M20.29N/AN/A$0.30 per share7.58
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.39N/AN/A$1.67 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%N/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$24.02M$0.606.63N/AN/A28.26%-39.65%26.54%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)

Latest CDXS, OPK, IRWD, and LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Codexis, Inc. stock logo
CDXS
Codexis
-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million
5/7/2026Q1 2026
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million
5/7/2026Q1 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
3/11/2026Q4 2025
Codexis, Inc. stock logo
CDXS
Codexis
$0.01$0.11+$0.10$0.11$35.83 million$38.92 million
3/5/2026Q4 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million
2/26/2026Q4 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.04+$0.03-$0.04$139.76 million$148.50 million
2/25/2026Q4 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.02-$0.01-$0.03-$0.01$86.10 million$47.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
0.94
5.36
5.23
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
1.41
1.41
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.24
18.80
18.77
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
3.50%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
9.30%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
25090.90 million87.72 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220163.06 million147.89 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140444.20 million382.01 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable

Recent News About These Companies

Spotlight On Promising Penny Stocks For May 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Codexis stock logo

Codexis NASDAQ:CDXS

$2.54 -0.11 (-4.15%)
As of 12:33 PM Eastern

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$3.98 -0.20 (-4.68%)
As of 12:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.28 -0.04 (-1.52%)
As of 12:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.12 -0.01 (-0.45%)
As of 12:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.